Survodutide vs Retatrutide — Dual Agonist vs Triple Agonist

How Do Survodutide and Retatrutide Compare?

Survodutide and retatrutide are both next-generation injectable obesity drugs that include glucagon receptor agonism in their mechanism of action — a feature that distinguishes them from GLP-1-only drugs like semaglutide and from dual GLP-1/GIP agonists like tirzepatide. The critical difference is the number of receptors they target: survodutide activates two (GLP-1 and glucagon), while retatrutide activates three (GLP-1, GIP, and glucagon).

They come from different companies — Boehringer Ingelheim develops survodutide, while Eli Lilly develops retatrutide — and are at slightly different stages of clinical development. Comparing them requires understanding what each receptor contributes, what the clinical data actually shows, and where cross-trial limitations make direct comparison unreliable.

What Is the Difference in Mechanism?

Survodutide (dual agonist): Activates the GLP-1 receptor (appetite suppression, glucose regulation) and the glucagon receptor (increased energy expenditure, hepatic lipid metabolism, potential lean mass preservation). The glucagon component is what separates survodutide from pure GLP-1 agonists. It is theorized to counteract some of the muscle loss associated with rapid weight reduction.

Retatrutide (triple agonist): Activates all three receptors — GLP-1, GIP, and glucagon. The GLP-1 and glucagon components overlap with survodutide’s mechanism. The addition of GIP receptor agonism is the structural differentiator. GIP (glucose-dependent insulinotropic polypeptide) contributes to insulin secretion and, based on preclinical and clinical data, may amplify weight loss when combined with GLP-1 agonism — as demonstrated by tirzepatide, which is a GLP-1/GIP dual agonist.

The central question in this comparison is whether the addition of GIP receptor agonism in retatrutide explains the higher weight loss figures seen in clinical trials. The answer is not definitively established. Retatrutide’s triple mechanism engages more metabolic pathways, but isolating the contribution of each receptor requires controlled studies that have not yet been published.

How Does the Weight Loss Data Compare?

Retatrutide reported 28.3% mean weight loss at 80 weeks on the 12 mg dose in the pivotal TRIUMPH-1 Phase 3 obesity trial (topline May 21, 2026), with the BMI ≥35 extension reaching 30.3% at 104 weeks. The dose-by-dose curve was 4 mg 19.0%, 9 mg 25.9%, 12 mg 28.3%, with 45.3% of 12 mg participants achieving ≥30% weight loss. TRIUMPH-4 separately reported 28.7% at 68 weeks (obesity with knee osteoarthritis). In its earlier Phase 2 trial (published in the New England Journal of Medicine, 2023), retatrutide showed 24.2% weight loss at 48 weeks with the 12 mg dose.

Survodutide now has its own Phase 3 result. SYNCHRONIZE-1, reported in May 2026, showed 16.6% mean weight loss at 76 weeks (up to 17.8 kg / 39.2 lbs) in obesity/overweight — the first Phase 3 obesity readout from Boehringer Ingelheim. That tracks closer to semaglutide than to tirzepatide, and analyst framing has noted it falls short of both tirzepatide and retatrutide. The dual-agonist programme retains a glucagon arm that leaves room for differentiation on cardiometabolic risk and liver fat.

Cross-trial caveat: These figures come from different trial designs, different patient populations, different dose ranges, and different time points. The 28.3% vs 16.6% gap is real as reported, but it does not constitute a head-to-head comparison. Until a randomised head-to-head trial is conducted (none is planned or registered), the comparison remains indirect. For retatrutide-specific dosing protocols and titration schedules, see the retatrutide dosage guide.

What Role Does Glucagon Play in Both Drugs?

Glucagon receptor agonism is the shared feature that sets both survodutide and retatrutide apart from the broader field of GLP-1-based obesity drugs. Most approved or late-stage obesity drugs — semaglutide, tirzepatide, oral semaglutide — do not include glucagon receptor activity.

The glucagon receptor contributes to energy expenditure by stimulating hepatic lipid oxidation and thermogenesis. In preclinical models, glucagon agonism has been associated with reduced liver fat, increased resting energy expenditure, and preservation of lean body mass during caloric restriction. These properties are of particular interest because muscle loss is a recognized concern with rapid weight loss from GLP-1 agonists. For a detailed exploration of this multi-receptor agonist pathway, see our dedicated analysis.

For survodutide, glucagon receptor agonism is half of the mechanism — it is a defining element of the drug’s profile. For retatrutide, glucagon is one of three receptor targets, working alongside GLP-1 and GIP. In both cases, the glucagon component is hypothesized to provide metabolic benefits beyond what GLP-1 agonism alone can deliver, though the clinical evidence for lean mass preservation in humans remains preliminary for both drugs.

Which One Is Better for MASH?

Survodutide is further along in MASH-specific clinical development. For the full compound profile, see Survodutide: Dual Agonist for Obesity & MASH. Boehringer Ingelheim runs two dedicated Phase 3 MASH trials — LIVERAGE (MASH with F2–F3 fibrosis) and LIVERAGE-Cirrhosis (compensated MASH cirrhosis) — and Phase 2 data showed significant improvements in liver fibrosis and MASH resolution. The glucagon component is central to the MASH hypothesis — glucagon receptor activation drives hepatic lipid oxidation, directly reducing liver fat accumulation.

Retatrutide has also shown liver benefits. Phase 2 data demonstrated substantial reductions in liver fat, and Eli Lilly has stated plans to study retatrutide in MASH. However, retatrutide’s MASH-specific clinical program is at an earlier stage than survodutide’s. If MASH is the primary research interest, survodutide currently has a more developed dataset and a more advanced dedicated trial program.

Which Is Closer to Approval?

As of May 23, 2026, neither survodutide nor retatrutide is approved by any regulatory agency, and neither company has publicly disclosed an NDA filing date. For individual regulatory timelines, see Is Survodutide Approved?

Retatrutide has three reported Phase 3 readouts: TRIUMPH-1 (pivotal obesity, 28.3% at 80 weeks on 12 mg, May 21, 2026), TRIUMPH-4 (obesity with knee osteoarthritis, December 2025), and TRANSCEND-T2D-1 (type 2 diabetes, March 2026). TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are expected later in 2026, and full TRIUMPH-1 data will be presented at the ADA Scientific Sessions in June 2026. For broader context, see our Retatrutide vs Tirzepatide vs CagriSema comparison. Survodutide has now reported SYNCHRONIZE-1 (16.6% at 76 weeks, May 2026) — BI’s first Phase 3 obesity result — with the rest of the SYNCHRONIZE programme still to read out.

In terms of data maturity, retatrutide is ahead on both volume and magnitude of Phase 3 evidence. Both drugs are plausibly 2027–2028 approval candidates, but this is speculative and subject to change based on remaining readouts and filing decisions. Researchers in the UAE can buy retatrutide in Dubai for in-vitro laboratory use today. For a ranked comparison of research compound suppliers, see our best retatrutide supplier Dubai guide.